open access

Vol 29, No 1 (2022)
Research Letter
Submitted: 2021-05-16
Accepted: 2021-08-04
Published online: 2021-09-30
Get Citation

Synergistic effects of levosimendan and convalescence plasma as bailout strategy in acute cardiogenic shock in COVID-19: A case report

Henrik Fox12, Jan F. Gummert12, Philipp Sommer23, Cornelius Knabbe4, Christian Sohns3
DOI: 10.5603/CJ.a2021.0119
·
Pubmed: 34622432
·
Cardiol J 2022;29(1):157-159.
Affiliations
  1. Clinic for Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
  2. Heart Failure Department, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
  3. Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
  4. Institute for Laboratory and Transfusion Medicine, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany

open access

Vol 29, No 1 (2022)
Research letters — COVID-19
Submitted: 2021-05-16
Accepted: 2021-08-04
Published online: 2021-09-30

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Synergistic effects of levosimendan and convalescence plasma as bailout strategy in acute cardiogenic shock in COVID-19: A case report

Journal

Cardiology Journal

Issue

Vol 29, No 1 (2022)

Article type

Research Letter

Pages

157-159

Published online

2021-09-30

Page views

3155

Article views/downloads

568

DOI

10.5603/CJ.a2021.0119

Pubmed

34622432

Bibliographic record

Cardiol J 2022;29(1):157-159.

Authors

Henrik Fox
Jan F. Gummert
Philipp Sommer
Cornelius Knabbe
Christian Sohns

References (10)
  1. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020; 5(7): 831–840.
  2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  3. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020; 323(16): 1561–1562.
  4. Gyoten T, Rojas SV, Irimie A, et al. Patients with ventricular assist device and cerebral entrapment-Supporting skullcap reimplantation. Artif Organs. 2021; 45(5): 473–478.
  5. Maack C, Eschenhagen T, Hamdani N, et al. Treatments targeting inotropy. Eur Heart J. 2019; 40(44): 3626–3644.
  6. Gyoten T, Morshuis M, Rojas SV, et al. Identification of characteristics, risk factors, and predictors of recurrent LVAD thrombosis: conditions in HeartWare devices. J Artif Organs. 2021; 24(2): 173–181.
  7. Flottmann C, Dumitrescu D, Sohns C, et al. Addition of levosimendan to overcome acute cardiogenic shock-Paving the way for later heart transplantation-A first case report. Clin Case Rep. 2021; 9(2): 856–860.
  8. Szymczyk T, Sauzet O, Paluszkiewicz LJ, et al. Non-invasive assessment of central venous pressure in heart failure: a systematic prospective comparison of echocardiography and Swan-Ganz catheter. Int J Cardiovasc Imaging. 2020; 36(10): 1821–1829.
  9. Mehta R, Leimberger J, Diepen Sv, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017; 376(21): 2032–2042.
  10. Gordon A, Perkins G, Singer M, et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med. 2016; 375(17): 1638–1648.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl